German biotech reports tumor shrinkage in rare eye cancer using experimental cell therapy
At a major European oncology meeting, a German biotech presented Phase 1 data showing tumor reduction in all 16 uveal melanoma patients treated with its experimental cell therapy.
During the flagship session of the European oncology conference, a German biotechnology firm unveiled results from its Phase 1 study of an experimental cell therapy. The trial enrolled 16 patients diagnosed with uveal melanoma, and each showed a measurable reduction in tumor size following treatment. Oncologist Sapna Patel interpreted the outcomes as a promising sign that the therapy’s target could be leveraged against more common, therapy-resistant cancers like pancreatic and ovarian malignancies.
The company positioned the data as a potential gateway to broader immunotherapy applications. While the results are preliminary, the presentation attracted significant attention from the global oncology community, reflecting the biotech's ambition to expand its pipeline beyond rare eye cancers.
Why it matters
Successful early results could open a new immunotherapy route for cancers that currently lack effective treatments.
In this story
